KAZ954 Combinations for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the safety and optimal dosage of a new treatment, KAZ954, used alone and with other drugs (PDR001, NIR178, and NZV930), for individuals with advanced solid tumors. The aim is to determine how well patients with metastatic, non-surgical cancer can tolerate these treatments. This trial suits those with metastatic cancer who are willing to undergo tumor biopsies. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that KAZ954, whether used alone or with other treatments, is generally safe and well tolerated. One study found no safety concerns with KAZ954, making future trials promising for people with advanced cancer. KAZ954 was safe at all tested doses, ranging from 150 mg to 1200 mg every two weeks.
For the combination treatments:
1. **KAZ954 + PDR001**: No safety concerns were found that would halt further studies. Preliminary data suggest it has a good safety profile.
2. **KAZ954 + NIR178**: This combination was also safe, with researchers reporting no significant safety issues.
3. **KAZ954 + NZV930**: Similarly, this combination raised no safety concerns, and previous studies did not highlight any major problems.
These findings suggest that the treatments are safe for further testing in humans, but this remains an early phase trial. Researchers are primarily focused on understanding the safety and correct dosage.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for advanced solid tumors because they introduce new mechanisms of action that differ from traditional therapies like chemotherapy and radiation. KAZ954 is unique as it targets specific pathways involved in tumor growth, potentially reducing cancer cell proliferation more precisely. When combined with PDR001, NZV930, or NIR178, KAZ954 may enhance the immune system's ability to attack cancer cells, offering a novel approach compared to conventional treatments. This combination strategy aims to improve efficacy and minimize side effects, providing hope for better outcomes in patients with advanced cancers.
What evidence suggests that this trial's treatments could be effective?
Research has shown that KAZ954, one of the treatments in this trial, may help treat advanced solid tumors. Studies have found it to be safe and well-tolerated, and it works by blocking a target called ENTPD2, which might help stop cancer cells from growing. In this trial, some participants will receive KAZ954 with PDR001, which can boost the immune system's ability to fight cancer by blocking certain pathways. Another group will receive the combination of KAZ954 with NZV930, aiming to improve treatment by targeting similar pathways, even though past data on NZV930 alone showed limited benefits. Additionally, early data suggest that using KAZ954 with NIR178, as tested in another arm of this trial, to block different cancer pathways simultaneously could enhance the treatment's effects. Overall, these combinations aim to better use the body's own defenses against cancer.34567
Who Is on the Research Team?
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
The dose escalation part estimated the MTD and/or RD and tested different dosing schedules.
Dose Expansion
Planned to use the MTD/RDE determined in the dose escalation part to assess the activity, safety, and tolerability of the investigational products.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- KAZ954
- NIR178
- NZV930
- PDR001
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
KAZ954 + NZV930
KAZ954 + NIR178
KAZ954 + PDR001
KAZ954
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD
Citations
1.
aacrjournals.org
aacrjournals.org/mct/article/22/12_Supplement/B114/730800/Abstract-B114-A-Phase-1-1b-study-of-KAZ954-aloneAbstract B114: A Phase 1/1b study of KAZ954 alone and in ...
KAZ was considered to be safe and well tolerated at all doses, and PK/PD analysis suggest effective ENTPD2 inhibition from a dose range of 150 to 1200 mg Q2W.
KAZ-954 - Drug Targets, Indications, Patents
The trial of NZV930 was “terminated early because data review showed low likelihood of efficacy in the patients recruited in that clinical ...
KAZ954 Alone and With PDR001, NZV930 and NIR178 in ...
This trial is testing a new drug called KAZ954 alone and with other drugs to find the safest and most effective dose for patients with advanced cancer.
Drugs targeting adenosine signaling pathways: A current ...
The FDA approved ticagrelor tablets in 2011 to reduce the rate of MI and cardiovascular death in adult patients with acute coronary syndrome (Table 1). The ...
Next steps for clinical translation of adenosine pathway ...
Preliminary data have demonstrated an optimal safety profile and enhanced overall response rates in several early phase clinical trials with ...
NCT04237649 | KAZ954 Alone and With PDR001, NZV930 ...
The primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose (RD) for expansion of single ...
Thank you!
The researchers concluded there were no safety concerns that would prevent future trials of KAZ954 alone or with PDR001 or NIR178 in people with advanced cancer ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.